Literature DB >> 10722229

Effective phage therapy is associated with normalization of cytokine production by blood cell cultures.

B Weber-Dabrowska1, M Zimecki, M Mulczyk.   

Abstract

The aim of this study was to investigate the effect of phagotherapy on tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) serum levels and the ability of blood cells to produce these cytokines in culture. Fifty one patients with long-term, suppurative infections of various tissues and organs were enrolled. The ability of cells to secrete cytokines was tested using whole blood cell cultures, unstimulated or stimulated with lipopolysaccharide (LPS) from E. coli. In addition, cytokine serum levels were determined. Measurement of cytokine activity was performed using bioassays. We showed that TNF-alpha, but not IL-6 serum levels, were regulated upon division of patients into categories exhibiting initial: low, moderate and high cytokine levels. The low spontaneous production of IL-6 by blood cell cultures was elevated significantly on day 21 of phage therapy, whereas high release of this cytokine was inhibited. No such correlation was observed with LPS-induced IL-6 production in cell cultures when cells from low-, moderately- or highly-reactive patients were studied. Phage therapy modified TNF release according to the initial ability to produce that cytokine: it reduced TNF production in high responders and increased it in low responders. Patients infected only with Gram-positive bacteria demonstrated analogous changes in the spontaneous and LPS-induced TNF-alpha production as in the whole studied group. A similar kind of regulation was observed in TNF-alpha and LPS-induced production, i.e. low production was significantly elevated, high strongly inhibited, and moderate only slightly affected. In summary, we demonstrated for the first time that effective phage therapy can normalize TNF-alpha serum levels and the production of TNF-alpha and IL-6 by blood cell cultures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722229

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  21 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus.

Authors:  Michał Zimecki; Jolanta Artym; Maja Kocieba; Beata Weber-Dabrowska; Jan Borysowski; Andrzej Górski
Journal:  Med Microbiol Immunol       Date:  2009-12-02       Impact factor: 3.402

3.  Safety of using Escherichia coli bacteriophages as a sanitizing agent based on inflammatory responses in rats.

Authors:  Ji-Yeon Hwang; Jung-Eun Kim; Yoon-Jae Song; Jong-Hyun Park
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

4.  Isolation and characterization of phage AHP-1 and its combined effect with chloramphenicol to control Aeromonas hydrophila.

Authors:  H P S U Chandrarathna; Chamilani Nikapitiya; S H S Dananjaya; B C J De Silva; Gang-Joon Heo; Mahanama De Zoysa; Jehee Lee
Journal:  Braz J Microbiol       Date:  2019-11-05       Impact factor: 2.476

5.  Effects of bacteriophages on free radical production and phagocytic functions.

Authors:  Anna Przerwa; Michał Zimecki; Kinga Switała-Jeleń; Krystyna Dabrowska; Ewa Krawczyk; Mirosław Łuczak; Beata Weber-Dabrowska; Danuta Syper; Ryszard Miedzybrodzki; Andrzej Górski
Journal:  Med Microbiol Immunol       Date:  2006-01-31       Impact factor: 3.402

6.  Transcriptional Profiling of a Cross-Protective Salmonella enterica serovar Typhimurium UK-1 dam Mutant Identifies a Set of Genes More Transcriptionally Active Compared to Wild-Type, and Stably Transcribed across Biologically Relevant Microenvironments.

Authors:  Claire B Miller; Sebastian Aguilar Pierlé; Kelly A Brayton; Jennine N Ochoa; Devendra H Shah; Kevin K Lahmers
Journal:  Pathogens       Date:  2014

7.  Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus.

Authors:  Michał Zimecki; Jolanta Artym; Maja Kocieba; Beata Weber-Dabrowska; Jan Borysowski; Andrzej Górski
Journal:  BMC Microbiol       Date:  2009-08-17       Impact factor: 3.605

8.  What are the limitations on the wider therapeutic use of phage?

Authors:  Alexandra Henein
Journal:  Bacteriophage       Date:  2013-04-01

Review 9.  A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.

Authors:  Xavier Wittebole; Sophie De Roock; Steven M Opal
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

Review 10.  Bacteriophage Procurement for Therapeutic Purposes.

Authors:  Beata Weber-Dąbrowska; Ewa Jończyk-Matysiak; Maciej Żaczek; Małgorzata Łobocka; Marzanna Łusiak-Szelachowska; Andrzej Górski
Journal:  Front Microbiol       Date:  2016-08-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.